CA2533873A1 - Method for attenuating virulence of microbial pathogens and for inhibiting microbial biofilm formation - Google Patents

Method for attenuating virulence of microbial pathogens and for inhibiting microbial biofilm formation Download PDF

Info

Publication number
CA2533873A1
CA2533873A1 CA002533873A CA2533873A CA2533873A1 CA 2533873 A1 CA2533873 A1 CA 2533873A1 CA 002533873 A CA002533873 A CA 002533873A CA 2533873 A CA2533873 A CA 2533873A CA 2533873 A1 CA2533873 A1 CA 2533873A1
Authority
CA
Canada
Prior art keywords
gmp
biofilm
microbial
aureus
leu
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002533873A
Other languages
English (en)
French (fr)
Inventor
David K.R. Karaolis
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2533873A1 publication Critical patent/CA2533873A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7084Compounds having two nucleosides or nucleotides, e.g. nicotinamide-adenine dinucleotide, flavine-adenine dinucleotide
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12Antidiarrhoeals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/02Local antiseptics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04Antibacterial agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02ATECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Molecular Biology (AREA)
  • Communicable Diseases (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Saccharide Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
CA002533873A 2003-07-28 2004-07-22 Method for attenuating virulence of microbial pathogens and for inhibiting microbial biofilm formation Abandoned CA2533873A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US49002903P 2003-07-28 2003-07-28
US60/490,029 2003-07-28
PCT/US2004/023498 WO2005030186A2 (en) 2003-07-28 2004-07-22 Method for attenuating virulence of microbial pathogens and for inhibiting microbial biofilm formation

Publications (1)

Publication Number Publication Date
CA2533873A1 true CA2533873A1 (en) 2005-04-07

Family

ID=34392905

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002533873A Abandoned CA2533873A1 (en) 2003-07-28 2004-07-22 Method for attenuating virulence of microbial pathogens and for inhibiting microbial biofilm formation

Country Status (7)

Country Link
US (1) US8367716B2 (enExample)
EP (1) EP1651242A2 (enExample)
JP (1) JP2007500697A (enExample)
AU (1) AU2004275696B2 (enExample)
CA (1) CA2533873A1 (enExample)
IL (1) IL173065A (enExample)
WO (1) WO2005030186A2 (enExample)

Families Citing this family (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4931798B2 (ja) * 2004-03-15 2012-05-16 ケイ.アール. カラオリス,デイヴィッド 免疫、炎症または神経保護応答のための方法
WO2006073514A2 (en) * 2004-08-25 2006-07-13 Tufts University Compositions, methods and kits for repressing virulence in gram positive bacteria
EP1782826A1 (en) * 2005-11-08 2007-05-09 GBF Gesellschaft für Biotechnologische Forschung mbH PQS and c-diGMP and its conjugates as adjuvants and their uses in pharmaceutical compositions
US8343536B2 (en) 2007-01-25 2013-01-01 Cook Biotech Incorporated Biofilm-inhibiting medical products
US8513305B2 (en) 2007-05-14 2013-08-20 Research Foundation Of State University Of New York Induction of a physiological dispersion response in bacterial cells in a biofilm
WO2009100456A2 (en) * 2008-02-08 2009-08-13 Prothera, Inc. Inhibition and treatment of gastrointestinal biofilms
WO2009133560A1 (en) * 2008-04-29 2009-11-05 Smart Assays Non-hydrolyzable and permeable cyclic bis-[nucleotide monophosphate] derivatives and uses thereof
US20120178710A1 (en) * 2009-07-01 2012-07-12 Rutgers, The State University Of New Jersey Synthesis of cyclic diguanosine monophosphate and thiophosphate analogs thereof
CN102199183B (zh) * 2010-03-26 2013-12-18 北京大学 环二鸟苷酸及其类似物和制备方法
CN101843899B (zh) * 2010-05-24 2012-11-07 中国人民解放军第三军医大学 耐甲氧西林金黄色葡萄球菌(mrsa)重组多亚单位基因工程疫苗及其制备方法
WO2012021554A1 (en) * 2010-08-09 2012-02-16 Yale University Cyclic di-gmp-ii riboswitches, motifs, and compounds, and methods for their use
US8450293B2 (en) 2010-08-10 2013-05-28 Rutgers, The State University Of New Jersey Synthesis and characterization of C8 analogs of c-di-GMP
NZ702392A (en) 2012-06-08 2017-03-31 Aduro Biotech Compositions and methods for cancer immunotherapy
EA201590396A1 (ru) 2012-12-13 2015-12-30 Адуро Биотек, Инк. Композиция, содержащая циклические пуриновые динуклеотиды с определенной стереохимией, и способ ее получения и применения
PT2934598T (pt) 2012-12-19 2018-07-24 Univ Texas Focalização farmacêutica de uma trajetória de sinalização de dinucleótido cíclico de mamífero
CN104152472A (zh) * 2012-12-28 2014-11-19 陶飞 一种双鸟苷酸环化酶基因、载体、工程菌及其应用
WO2014109256A1 (ja) * 2013-01-09 2014-07-17 国立大学法人東北大学 トリアゾール連結型環状ジヌクレオチド類縁体
ES2982836T3 (es) 2013-04-29 2024-10-17 Memorial Sloan Kettering Cancer Center Composiciones y métodos para alterar la señalización de segundos mensajeros
EP2992000B1 (en) 2013-05-03 2020-07-08 The Regents of The University of California Cyclic di-nucleotide induction of type i interferon
ME03586B (me) * 2013-05-18 2020-07-20 Univ California Sastavi i metode za aktiviranje signaliziranja koje je zavisno od .,stimulatora gena za interferon"
US9549944B2 (en) * 2013-05-18 2017-01-24 Aduro Biotech, Inc. Compositions and methods for inhibiting “stimulator of interferon gene”—dependent signalling
WO2014189806A1 (en) * 2013-05-18 2014-11-27 Aduro Biotech, Inc. Compositions and methods for inhibiting "stimulator of interferon gene" dependent signalling
US10176292B2 (en) 2013-07-31 2019-01-08 Memorial Sloan-Kettering Cancer Center STING crystals and modulators
US9315523B2 (en) 2013-12-06 2016-04-19 Rutgers, The State University Of New Jersey Cyclic dinucleosides
WO2015185565A1 (en) 2014-06-04 2015-12-10 Glaxosmithkline Intellectual Property Development Limited Cyclic di-nucleotides as modulators of sting
GB201501462D0 (en) 2015-01-29 2015-03-18 Glaxosmithkline Ip Dev Ltd Novel compounds
JO3746B1 (ar) 2015-03-10 2021-01-31 Aduro Biotech Inc تركيبات وطرق لتنشيط الإشارات المعتمدة على "منبه أو تحفيز جين انترفيرون"
JP6411676B2 (ja) 2015-12-03 2018-10-24 グラクソスミスクライン、インテレクチュアル、プロパティー、ディベロップメント、リミテッドGlaxosmithkline Intellectual Property Development Limited Stingの調節因子としての環状プリンジヌクレオチド
CN114751950B (zh) 2016-03-18 2025-04-18 免疫传感器公司 环二核苷酸化合物及使用方法
EP3507367A4 (en) 2016-07-05 2020-03-25 Aduro BioTech, Inc. CYCLIC DINUCLEOTID COMPOUNDS WITH INCLUDED NUCLEIC ACIDS AND USES THEREOF
PT3512861T (pt) 2016-12-01 2021-04-29 Takeda Pharmaceuticals Co Dinucleotídeos cíclicos
KR102782200B1 (ko) * 2017-08-30 2025-03-17 에이제이 사이언시즈 (이씽) 코., 엘티디 인터페론 유전자 조절인자의 자극제로서의 환식 다이-뉴클레오타이드
MX2020004858A (es) 2017-11-10 2020-10-01 Takeda Pharmaceuticals Co Compuestos moduladores de sting y metodos de elaboracion y uso.
US11541105B2 (en) 2018-06-01 2023-01-03 The Research Foundation For The State University Of New York Compositions and methods for disrupting biofilm formation and maintenance
WO2020031083A1 (en) * 2018-08-06 2020-02-13 KHAN, Khalid Antimicrobial formulations comprising vancomycin or tobramycin
AU2020267486B2 (en) 2019-05-09 2025-12-18 Aligos Therapeutics, Inc. Modified cyclic dinucleoside compounds as STING modulators
CN114085887A (zh) * 2020-08-25 2022-02-25 中国科学院大连化学物理研究所 一种基于仿生微球的铜绿假单胞菌耐药浓度的检测方法
MX2023005381A (es) 2020-11-09 2023-05-23 Takeda Pharmaceuticals Co Conjugados de anticuerpo y farmaco.
CN114099657B (zh) * 2021-11-04 2022-05-17 暨南大学 一种溶藻弧菌减毒活疫苗及其制备方法与应用
KR102551061B1 (ko) * 2022-05-26 2023-07-03 중앙대학교 산학협력단 Saha를 유효성분으로 포함하는 살모넬라 속 균주에 의한 바이오필름 생성 저해용 조성물
CN118956719B (zh) * 2024-07-31 2025-05-09 武汉市仪泰环境科技有限公司 一种毒性检测中加快微生物挂膜的方法

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5268274A (en) * 1989-04-12 1993-12-07 Cetus Corporation Methods and nucleic acid sequences for the expression of the cellulose synthase operon
CA2109084C (en) * 1991-05-03 2004-02-24 University Technologies International, Inc. Biofilm reduction method
GB2257704B (en) 1991-07-18 1995-03-01 Erba Carlo Spa Cyclic oligonucleotides phosphorothioates
US20020091074A1 (en) * 2000-09-20 2002-07-11 Wooley Richard E. Medical compositions, dressings and methods for treating microbial infections of skin lesions
US20020169288A1 (en) * 2001-03-15 2002-11-14 Magnus Hook Collagen-binding adhesin from staphylococcus epidermidis and method of use
JP2002302404A (ja) * 2001-04-02 2002-10-18 Shiseido Co Ltd 抗菌防黴助剤
US7189351B2 (en) * 2001-10-25 2007-03-13 Spherix Incorporated D-tagatose as an anti-biofilm agent

Also Published As

Publication number Publication date
WO2005030186A2 (en) 2005-04-07
WO2005030186A3 (en) 2005-07-14
IL173065A0 (en) 2006-06-11
EP1651242A2 (en) 2006-05-03
US8367716B2 (en) 2013-02-05
IL173065A (en) 2011-05-31
US20070244059A1 (en) 2007-10-18
AU2004275696A1 (en) 2005-04-07
JP2007500697A (ja) 2007-01-18
AU2004275696B2 (en) 2010-02-18

Similar Documents

Publication Publication Date Title
AU2004275696B2 (en) Method for attenuating virulence of microbial pathogens and for inhibiting microbial biofilm formation
Langendonk et al. The building blocks of antimicrobial resistance in Pseudomonas aeruginosa: implications for current resistance-breaking therapies
Mitchell et al. Staphylococcus aureus sigma B-dependent emergence of small-colony variants and biofilm production following exposure to Pseudomonas aeruginosa 4-hydroxy-2-heptylquinoline-N-oxide
Kaye et al. Pathogens resistant to antimicrobial agents: epidemiology, molecular mechanisms, and clinical management
Russell Mechanisms of bacterial resistance to antibiotics and biocides
Van Laar et al. Sublethal concentrations of carbapenems alter cell morphology and genomic expression of Klebsiella pneumoniae biofilms
Abebe et al. A review on molecular mechanisms of bacterial resistance to antibiotics
Honma et al. Role of a Tannerella forsythia exopolysaccharide synthesis operon in biofilm development
Espinel et al. Multiple roles of putrescine and spermidine in stress resistance and virulence of Salmonella enterica serovar Typhimurium
Klahn et al. New structural templates for clinically validated and novel targets in antimicrobial drug research and development
Martinez Mechanisms of action and of resistance to quinolones
Hemlata et al. The ever changing face of antibiotic resistance: Prevailing problems and preventive measures
Jolivet‐Gougeon et al. Bacterial Persistence in Biofilms and Antibiotics: Mechanisms Involved
KR101633265B1 (ko) 바이오필름에 의해서 유발되는 감염증의 예방 또는 치료를 위한 약학적 조성물, 및 바이오필름 형성을 억제하기 위한 코팅용 조성물
Wagley et al. A proteasome inhibitor produced by Burkholderia pseudomallei modulates intracellular growth
Ravishankar Investigation of antibiofilm and antivirulence activity of 5-fluorocytosine in Escherichia coli
Kanwar et al. Oral Microbiome and Drug Resistance
Elkrewi Investigating the prevalence and genetic basis of resistance to the antimicrobial agents bacitracin, nitrofurantoin and silver in key pathogenic bacteria
Thapa From Regulation of Secondary Metabolites to Increased Virulence under Sublethal Dosage of Antibiotics: An Unprecedented Role of Global Regulator, MftR, in Burkholderia thailandensis
Krath Investigation of a cryptic aminoglycoside resistance gene in Salmonella Enterica subspecies Enterica Serovar typhimurium
Puig Collderram Optimization of therapeutic options against multidrug resistant microorganisms
Scoffone et al. Antimicrobial drug efflux pumps in Burkholderia
Surati et al. Antibiotics and Plant-Derived Antimicrobials as an Alternative Source to Control Infections
Ih Mechanisms and PK/PD modelling of MCR-1-induced adaptive resistance in Enterobacteriaceae
Reynolds Cyclic di-GMP Regulates Motility, Biofilm Formation, and Desiccation Tolerance in Acinetobacter baumannii

Legal Events

Date Code Title Description
EEER Examination request
FZDE Discontinued

Effective date: 20130723